Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Completed · Phase 1
Conditions studied: Malignant Glioma
In brief
RATIONALE: Oncolytic viruses such as reovirus (REOLYSIN®) can specifically kill tumor cells while leaving healthy cells unharmed. PURPOSE: This phase I/II study investigates the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and anti-tumor effect of intralesional administration of REOLYSIN® therapeutic reovirus in patients with malignant glioma with evaluable disease which is progressive/recurrent despite surgery and/or radiotherapy with or without chemotherapy. (The phase I portion of the study is currently enrolling patients.)
Key facts
- Study ID
- NCT00528684
- Run by
- Oncolytics Biotech
- People needed
- 18
- Starts
- 2006-07-01
- Expected to finish
- 2010-06-01
- Last updated by the study team
- 2014-10-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham — Birmingham, Alabama, United States
- Cedars-Sinai Medical Center — Los Angeles, California, United States
- The Ohio State University Medical Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.